ANZCTR search results

These search results are from the Australian New Zealand Clinical Trials Registry (ANZCTR).

You can narrow down the results using the filters

First, select a broad health condition.
32696 results sorted by trial registration date.
Clear all

  • Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

    This phase 1b trial is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) and pembrolizumab in patients with metastatic castration resistant prostate cancer (mCRPC).

    Registration number:
    NCT07090369
    Broad health category:
    • Metastatic Castrate Resistant Prostate Cancer (mCRPC)
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Not yet recruiting
    Recruitment sites:
    • VIC
    • Not specified
    Gender:
    • All

  • A Study of YP05002 in Healthy Participants

    This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, efficacy, food effect of YP05002 Tablets in healthy participants

    Registration number:
    NCT07089823
    Broad health category:
    • Weight Management
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • VIC
    • Not specified
    Gender:
    • All

  • A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

    AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.

    Registration number:
    NCT07088926
    Broad health category:
    • Bronchiectasis With Pseudomonas Aeruginosa Colonization
    Specific health category:
    • Not specified
    Trial focus:
    • Prevention
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • Not specified
    Gender:
    • All

  • A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma

    This is Phase I, open label, multi-center clinical trial evaluating an investigational treatment, Adze1.C. Adze1.C is a type of oncolytic virus therapy for adults with advanced Melanoma that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight tumors. The purpose of this study is to determine the safety of Adze1.C, how well it is tolerated, and to identify the highest dose that can be safely given.

    Registration number:
    NCT07086105
    Broad health category:
    • Metastatic Melanoma
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • QLD
    • SA
    • VIC
    • Not specified
    Gender:
    • All

  • Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

    Registration number:
    NCT07085767
    Broad health category:
    • Breast Cancer
    • Locally Advanced Breast Cancer
    • Metastatic Breast Cancer
    • ER Positive Breast Cancer
    • HER2 Negative Breast Carcinoma
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • NSW
    • QLD
    • SA
    • VIC
    • WA
    • Not specified
    Gender:
    • All

  • A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults

    The purpose of this study is to assess the safety of 3 doses of 2 new Strep A vaccine formulations, one with an Alum adjuvant, and the other with AS37 adjuvant. The Strep A vaccine will be tested for the first time in humans, in healthy young adults 18 to 25 years of age. The study will also assess if the vaccines have any immediate reactions and if they induce an immune response. A low, medium, and high dose of each formulation of the vaccine will be assessed in sequence.

    Registration number:
    NCT07085702
    Broad health category:
    • Streptococcal Infections
    Specific health category:
    • Not specified
    Trial focus:
    • Prevention
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • NSW
    • VIC
    • Not specified
    Gender:
    • All

  • Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients

    Part 1 of this study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VT7208 in healthy volunteers. Part 2 of this study will be an open-label, randomized study to characterize the effect of food on the pharmacokinetics of VT7208 in healthy volunteers. Part 3 of this study will evaluate the safety of VT7208 as monotherapy in patients with MS.

    Registration number:
    NCT07085507
    Broad health category:
    • Multiple Sclerosis
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • SA
    • Not specified
    Gender:
    • All

  • Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

    The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

    Registration number:
    NCT07084896
    Broad health category:
    • Multiple Myeloma
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Active, not recruiting
    Recruitment sites:
    • VIC
    • Not specified
    Gender:
    • All

  • OM336 in Autoimmune Cytopenias

    An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.

    Registration number:
    NCT07083960
    Broad health category:
    • AIHA - Warm Autoimmune Hemolytic Anemia
    • AIHA - Cold Autoimmune Hemolytic Anemia
    • ITP - Immune Thrombocytopenia
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • ACT
    • NSW
    • QLD
    • Not specified
    Gender:
    • All

  • TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

    The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas

    Registration number:
    NCT07082803
    Broad health category:
    • Lymphoma
    • Lymphoma, Non Hodgkin
    Specific health category:
    • Not specified
    Trial focus:
    • Treatment
    Recruitment status:
    • Recruiting
    Recruitment sites:
    • NSW
    • QLD
    • VIC
    • WA
    • Not specified
    Gender:
    • All
Tags:
  • Finding clinical trials